- Oculis (OCS, Financial) is progressing with three key pipeline assets, including ongoing late-stage clinical trials.
- Privosegtor's development expands into two new indications: NAION and MS relapses.
- The company has over 800 patients enrolled in large-scale Phase 3 DME trials.
Oculis Holding AG (OCS) conducted an R&D event to showcase developments in its three pipeline assets, underscoring its commitment to addressing unmet medical needs in ophthalmic and neuro-ophthalmic diseases. The event featured updates on significant clinical trials and future development plans.
Key highlights included progress in the DIAMOND and EMERALD Phase 3 trials for diabetic macular edema (DME), with both studies having completed enrollment of over 800 patients. Oculis anticipates delivering topline data from these trials in the second quarter of 2026.
Oculis also revealed its development plans for Licaminlimab (OCS-02), focusing on dry eye disease. A Phase 2/3 study is expected to commence in the second half of 2025. This trial will utilize a genotype-based approach to advance personalized medicine in dry eye disease treatment.
The ACUITY Phase 2 trial has generated new data for Privosegtor (OCS-05), aimed at treating acute optic neuritis. Furthermore, Oculis is exploring the expansion of Privosegtor into two new indications: non-arteritic anterior ischemic optic neuropathy (NAION) and relapses of multiple sclerosis (MS), reflecting its potential broad applicability in neuro-ophthalmic conditions.
A subsequent investor meeting is scheduled in Iceland on April 29, 2025, where further discussions on Oculis' late-stage pipeline will take place.
